# focal segmental glomerulosclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/focal-segmental-glomerulosclerosis

> 2 upcoming FDA catalysts in focal segmental glomerulosclerosis: praliciguat (part a, AKBA) on June 2027 (primary completion); praliciguat (part a, AKBA) on Jun to Sep 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 17, 2025 | [FILSPARI (sparsentan) NDA/BLA submission](https://sec-api.dev/pdufa/sparsentan) | TVTX | focal segmental glomerulosclerosis | completed | "On March 17, 2025, Travere Therapeutics, Inc. (the "Company") announced that it has submitted a supplemental New Drug Application ("sNDA") to the U.S. Food and Drug Administration ("FDA") seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000012/tvtx-20250317.htm)) |
| May 15, 2025 | [FILSPARI (sparsentan) NDA/BLA acceptance](https://sec-api.dev/pdufa/sparsentan) | TVTX | focal segmental glomerulosclerosis | completed | "On May 15, 2025, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has accepted its supplemental New Drug Application ("sNDA") for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000032/tvtx-20250515.htm)) |
| June 2027 | [Praliciguat (part a) primary completion](https://sec-api.dev/pdufa/praliciguat-part-a) | AKBA | Focal Segmental Glomerulosclerosis | scheduled | "NCT07268638 (A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07268638)) |
| Jun to Sep 2027 | [Praliciguat (part a) topline data readout](https://sec-api.dev/pdufa/praliciguat-part-a) | AKBA | Focal Segmental Glomerulosclerosis | scheduled | "NCT07268638 (A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07268638)) |

## Drugs

- [FILSPARI (sparsentan)](https://sec-api.dev/pdufa/sparsentan) (TVTX)
- [Praliciguat (part a)](https://sec-api.dev/pdufa/praliciguat-part-a) (AKBA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/focal-segmental-glomerulosclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "focal segmental glomerulosclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/focal-segmental-glomerulosclerosis

```bibtex
@misc{secapidev_indications_focal_segmental_glomerulosclerosis_20261116,
  title        = {focal segmental glomerulosclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/focal-segmental-glomerulosclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_focal_segmental_glomerulosclerosis_20261116","title":"focal segmental glomerulosclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/focal-segmental-glomerulosclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
